mAbTree Biologics has signed a co-development and commercialistion agreement with Shilpa Biologicals for its monoclonal antibody.
The exclusive deal will see Shilpa Biologicals acquire mAbTree Biologics' novel biologic; a checkpoint inhibitor designed for immuno-oncological indications.
Through this agreement, Shilpa will support the asset's development and commercialisation — including the biologic's GMP manufacturing.
Shilpa will also provide mAbTree access to India and several other global markets.
The human monoclonal antibody is designed to promote T cell activation, facilitating immune response in a similar way to PD-1/PD-L1 blockades.
mAbTree and Shilpa plan to commercialise the candidate as both a mono and combinatorial therapy — diminishing tumour metastasis and increasing tumour susceptibility to chemotherapy.
According to mAbTree, the technology is suitable for various cancer types, including lung, head and neck, and haematological malignancies.
Under the terms of the agreement, Shilpa Biologics will use its R&D teams to assist in cell line development and GMP drug product manufacturing, with all production occurring at the company's biomanufacturing facility in Dharwad, Karnataka.
Commenting on the co-development deal and its potential impact on patients, Dr Sridevi Khambhampaty, CEO Shilpa Biologicals: “This novel therapy represents a new frontier in immuno-oncology, with the potential to expand treatment for patients who do not benefit from current immunotherapy options – so it’s potentially a massive breakthrough.”
“mAbTree is excited to continue our strategic partnership with Shilpa Biologicals and our aim is to enable greater access to medicines for more patients across the world, especially focusing on India and ROW markets where access has been limited”, added Mr Raj Andhuvan, CEO mAbTree.
“But what really impresses us about Shilpa is their commitment and scientific expertise. We look forward to rapidly advancing therapeutic options in the NBE space and to addressing emerging health challenges.”